8,340,000 Shares of Common Stock ($0.001 Par Value) Pre-Funded Warrants to Purchase Up to 5,260,000 Shares of Common Stock Series 1 Warrants to Purchase Up to 6,800,000 Shares of Common Stock Series 2 Warrants to Purchase up to 6,800,000 Shares of...Equity Underwriting Agreement • December 18th, 2020 • Scynexis Inc • Pharmaceutical preparations • New York
SCYNEXIS, Inc., a Delaware corporation (the “Issuer”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom Guggenheim Securities, LLC is acting as representative (“you” or the “Representative”) an aggregate of (i) 8,340,000 shares (the “Shares”) of the Issuer’s common stock, $0.001 par value (the “Common Stock”), (ii) pre-funded warrants to purchase up to an aggregate of 5,260,000 shares of Common Stock at an exercise price of $0.001 per share (the “Pre-Funded Warrants”), (iii) Series 1 warrants, each of which can be exercised to purchase 0.50 of a share of Common Stock and, in the aggregate, to purchase up to 6,800,000 shares of Common Stock (the “Series 1 Warrants”) and (iv) Series 2 warrants, each of which can be exercised to purchase 0.50 of a share of Common Stock and, in the aggregate, to purchase up to 6,800,000 shares of Common Stock (the “Series 2 Warrants” and, together with the Pre-Funded Warrants and the Series 1 Warrants, t
